Attached files
| file | filename |
|---|---|
| EX-21.1 - EX-21.1 - Atea Pharmaceuticals, Inc. | d913778dex211.htm |
| EX-10.7 - EX-10.7 - Atea Pharmaceuticals, Inc. | d913778dex107.htm |
| EX-10.6 - EX-10.6 - Atea Pharmaceuticals, Inc. | d913778dex106.htm |
| EX-10.1 - EX-10.1 - Atea Pharmaceuticals, Inc. | d913778dex101.htm |
| EX-4.2 - EX-4.2 - Atea Pharmaceuticals, Inc. | d913778dex42.htm |
| EX-4.1 - EX-4.1 - Atea Pharmaceuticals, Inc. | d913778dex41.htm |
| EX-3.2 - EX-3.2 - Atea Pharmaceuticals, Inc. | d913778dex32.htm |
| EX-3.1 - EX-3.1 - Atea Pharmaceuticals, Inc. | d913778dex31.htm |
| S-1 - S-1 - Atea Pharmaceuticals, Inc. | d913778ds1.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Atea Pharmaceuticals, Inc.:
We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
Boston, Massachusetts
October 9, 2020